Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 124 participants.

Also called NCT05114590

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 124 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05114590
  • WHO UTN U1111-1261-7399
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05114590. Allocation not applicable; no masking; primary purpose treatment. Start 2022-01-27 (actual); primary completion 2023-03-28 (actual). Results posted on 2024-05-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
Acronym
Soli-CGM
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Insulin glargine/Lixisenatide
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct05114590
Content hash
4584c4410ee10e67a9f1c21a93217b43da2cdde595946ac878ef503e4d083bf6